Action plans for COPD: Strategies to manage exacerbations and improve outcomes

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 1179-1188

  Jalota, Leena ^a   Jain, Vipul V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Exacerbations; Integrated disease management program; Self management

Indexed keywords

ANTIBIOTIC AGENT; STEROID;

ASTHMA; BACTERIAL LOAD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COMORBIDITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; HEALTH CARE UTILIZATION; HEART FAILURE; HOSPITAL READMISSION; HUMAN; LUNG EMBOLISM; OUTCOME ASSESSMENT; PHENOTYPE; PRACTICE GUIDELINE; PULMONARY REHABILITATION; REVIEW; SELF CARE; SLEEP DISORDERED BREATHING; SMOKING CESSATION PROGRAM; SOCIAL PSYCHOLOGY; SPIROMETRY; SYMPTOMATOLOGY; TREATMENT PLANNING; ATTITUDE TO HEALTH; COMPREHENSION; DISEASE COURSE; DISEASE MANAGEMENT; HEALTH STATUS; INTEGRATED HEALTH CARE SYSTEM; LUNG; MENTAL HEALTH; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PROCEDURES; PSYCHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

COMORBIDITY; COMPREHENSION; DELIVERY OF HEALTH CARE, INTEGRATED; DISEASE MANAGEMENT; DISEASE PROGRESSION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH STATUS; HUMANS; LUNG; MENTAL HEALTH; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SELF CARE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84973449198     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S76970     Document Type: Review

References (78)

1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006; 28(3): 523-532.
2. Shah T, Churpek MM, Perraillon MC, Konetzka RT. Understanding why patients with COPD get readmitted: a large national study to delineate the Medicare population for the readmissions penalty expansion. Chest. 2015; 147(5): 1219-1226.
3. Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012; 7: 757-764.
4. Miller JD, Foster T, Boulanger L, et al. Direct costs of COPD in the U. S.: an analysis of Medical Expenditure Panel Survey (MEPS) data. COPD. 2005; 2(3): 311-318.
5. Cowie RL, Revitt SG, Underwood MF, Field SK. The effect of a peak flow-based action plan in the prevention of exacerbations of asthma. Chest. 1997; 112(6): 1534-1538.
6. [No authors listed]. Effectiveness of routine self monitoring of peak flow in patients with asthma. BMJ. 1994; 308(6928): 564-567.
7. Sheares BJ, Mellins RB, Dimango E, et al. Do patients of subspecialist physicians benefit from written asthma action plans? Am J Respir Crit Care Med. 2015; 191(12): 1374-1383.
8. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999; 340(25): 1941-1947.
9. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999; 354(9177): 456-460.
10. Self TH, Patterson SJ, Headley AS, Finch CK. Action plans to reduce hospitalizations for chronic obstructive pulmonary disease exacerbations: focus on oral corticosteroids. Curr Med Res Opin. 2014; 30(12): 2607-2615.
11. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med. 2003; 163(5): 585-591.
12. Rice KL, Dewan N, Bloomfield HE, et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2010; 182(7): 890-896.
13. Sridhar M, Taylor R, Dawson S, Roberts NJ, Partridge MR. A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2008; 63(3): 194-200.
14. Effing T, Kerstjens H, van der Valk P, Zielhuis G, van der Palen J. (Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study. Thorax. 2009; 64(11): 956-962.
15. Fan VS, Gaziano JM, Lew R, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med. 2012; 156(10): 673-683.
16. Woods JA, Wheeler JS, Finch CK, Pinner NA. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014; 9: 421-430.
17. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013; 309(21): 2223-2231.
18. Walters JA, Tan DJ, White CJ, Wood-Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014; 12: CD006897.
19. de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest. 2007; 132(6): 1741-1747.
20. Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002; 165(5): 698-703.
21. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106(2): 196-204.
22. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000; 117(5): 1345-1352.
23. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000; 117(6): 1638-1645.
24. Allegra L, Blasi F, Diano P, et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med. 2005; 99(6): 742-747.
25. Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA, et al. Relation of sputum colour to bacterial load in acute exacerbations of COPD. Respir Med. 2009; 103(4): 601-606.
26. Llor C, Moragas A, Hernandez S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186(8): 716-723.
27. Miravitlles M, Moragas A, Hernandez S, Bayona C, Llor C. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? Chest. 2013; 144(5): 1571-1577.
28. Roede BM, Bresser P, Prins JM, Schellevis F, Verheij TJ, Bindels PJ. Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. Eur Respir J. 2009; 33(2): 282-288.
29. Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax. 2003; 58(1): 37-42.
30. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164(9): 1618-1623.
31. Zwerink M, Brusse-Keizer M, van der Valk PD, et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014; 3: CD002990.
32. Sedeno MF, Nault D, Hamd DH, Bourbeau J. A self-management education program including an action plan for acute COPD exacerbations. COPD. 2009; 6(5): 352-358.
33. Jain VV, Allison R, Beck SJ, et al. Impact of an integrated disease management program in reducing exacerbations in patients with severe asthma and COPD. Respir Med. 2014; 108(12): 1794-1800.
34. Benzo RP, Kirsch JL, Dulohery MM, Abascal-Bolado B. Emotional intelligence: a novel outcome associated with wellbeing and self-management in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016; 13(1): 10-16.
35. Bryant J, McDonald VM, Boyes A, Sanson-Fisher R, Paul C, Melville J. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir Res. 2013; 14: 109.
36. Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2010; 5: 401-406.
37. Kessler R, Stahl E, Vogelmeier C, et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest. 2006; 130(1): 133-142.
38. Ng LW, Mackney J, Jenkins S, Hill K. Does exercise training change physical activity in people with COPD? A systematic review and meta-analysis. Chron Respir Dis. 2012; 9(1): 17-26.
39. Garcia-Aymerich J, Pitta F. Promoting regular physical activity in pulmonary rehabilitation. Clin Chest Med. 2014; 35(2): 363-368.
40. Bischoff EW, Hamd DH, Sedeno M, et al. Effects of written action plan adherence on COPD exacerbation recovery. Thorax. 2011; 66(1): 26-31.
41. Bucknall CE, Miller G, Lloyd SM, et al. Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial. BMJ. 2012; 344: e1060.
42. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000; 160(14): 2101-2107.
43. Turan O, Yemez B, Itil O. The effects of anxiety and depression symptoms on treatment adherence in COPD patients. Prim Health Care Res Dev. 2014; 15(3): 244-251.
44. Han MK, Kim MG, Mardon R, et al. Spirometry utilization for COPD: how do we measure up? Chest. 2007; 132(2): 403-409.
45. Jain VV, Allison DR, Andrews S, Mejia J, Mills PK, Peterson MW. Misdiagnosis among frequent exacerbators of clinically diagnosed asthma and COPD in absence of confirmation of airflow obstruction. Lung. 2015; 193(4): 505-512.
46. Sokol KC, Sharma G, Lin YL, Goldblum RM. Choosing wisely: adherence by physicians to recommended use of spirometry in the diagnosis and management of adult asthma. Am J Med. 2015; 128(5): 502-508.
47. Albers M, Schermer T, Molema J, et al. Do family physicians' records fit guideline diagnosed COPD? Fam Pract. 2009; 26(2): 81-87.
48. Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008; 63(5): 402-407.
49. Martinez CH, Mannino DM, Jaimes FA, et al. Undiagnosed obstructive lung disease in the United States: associated factors and long-term mortality. Ann Am Thorac Soc. 2015; 12(12): 1788-1795.
50. Walters JA, Hansen EC, Walters EH, Wood-Baker R. Under-diagnosis of chronic obstructive pulmonary disease: a qualitative study in primary care. Respir Med. 2008; 102(5): 738-743.
51. Ghattas C, Dai A, Gemmel DJ, Awad MH. Over diagnosis of chronic obstructive pulmonary disease in an underserved patient population. Int J Chron Obstruct Pulmon Dis. 2013; 8: 545-549.
52. Schermer TR, Smeele IJ, Thoonen BP, et al. Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. Eur Respir J. 2008; 32(4): 945-952.
53. Zwar NA, Marks GB, Hermiz O, et al. Predictors of accuracy of diagnosis of chronic obstructive pulmonary disease in general practice. Med J Aust. 2011; 195(4): 168-171.
54. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma. 2006; 43(1): 75-80.
55. Izquierdo JL, Martin A, de Lucas P, Rodriguez-Gonzalez-Moro JM, Almonacid C, Paravisini A. Misdiagnosis of patients receiving inhaled therapies in primary care. Int J Chron Obstruct Pulmon Dis. 2010; 5: 241-249.
56. Collins BF, Ramenofsky D, Au DH, Ma J, Uman JE, Feemster LC. The association of weight with the detection of airflow obstruction and inhaled treatment among patients with a clinical diagnosis of COPD. Chest. 2014; 146(6): 1513-1520.
57. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Bethesda (MD): GOLD; 2015. Available from: http: //www. goldcopd. org/guidelines-global-strategy-for-diagnosis-management. html. Accessed April 20, 2016.
58. Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 2015; 10: 95-109.
59. Sharafkhaneh A, Petersen NJ, Yu HJ, Dalal AA, Johnson ML, Hanania NA. Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population. Int J Chron Obstruct Pulmon Dis. 2010; 5: 125-132.
60. Soler X, Gaio E, Powell FL, et al. High prevalence of obstructive sleep apnea in patients with moderate to severe chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2015; 12(8): 1219-1225.
61. Tillie-Leblond I, Marquette CH, Perez T, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med. 2006; 144(6): 390-396.
62. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail. 2006; 8(7): 706-711.
63. Caminati A, Cavazza A, Sverzellati N, Harari S. An integrated approach in the diagnosis of smoking-related interstitial lung diseases. Eur Respir Rev. 2012; 21(125): 207-217.
64. Margaritopoulos GA, Vasarmidi E, Jacob J, Wells AU, Antoniou KM. Smoking and interstitial lung diseases. Eur Respir Rev. 2015; 24(137): 428-435.
65. Walsh SL, Nair A, Desai SR. Interstitial lung disease related to smoking: imaging considerations. Curr Opin Pulm Med. 2015; 21(4): 407-416.
66. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186(2): 155-161.
67. Xu W, Collet JP, Shapiro S, et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med. 2008; 178(9): 913-920.
68. Jennings JH, Digiovine B, Obeid D, Frank C. The association between depressive symptoms and acute exacerbations of COPD. Lung. 2009; 187(2): 128-135.
69. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007; 167(1): 60-67.
70. Paz-Diaz H, Montes de Oca M, Lopez JM, Celli BR. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehabil. 2007; 86(1): 30-36.
71. Yohannes AM, Baldwin RC, Connolly MJ. Prevalence of sub-threshold depression in elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 2003; 18(5): 412-416.
72. Postma DS, Reddel HK, ten Hacken NH, van den Berge M. Asthma and chronic obstructive pulmonary disease: similarities and differences. Clin Chest Med. 2014; 35(1): 143-156.
73. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003; 124(2): 474-481.
74. Menezes AM, Montes de Oca M, Perez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014; 145(2): 297-304.
75. Cottin V, Cordier JF. Combined pulmonary fibrosis and emphysema: an experimental and clinically relevant phenotype. Am J Respir Crit Care Med. 2005; 172(12): 1605; author reply 1605-1606.
76. Jankowich MD, Rounds SI. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012; 141(1): 222-231.
77. Agusti A. Phenotypes and disease characterization in chronic obstructive pulmonary disease: toward the extinction of phenotypes? Ann Am Thorac Soc. 2013; 10 Suppl: S125-S130.
78. Burgel PR, Sethi S, Kim V. Chronic obstructive pulmonary disease phenotypes: past, present, and future. Ann Am Thorac Soc. 2015; 12(3): 289-290.